New MRD Publication In Unresectable Stage I-III Lung Cancer Demonstrates Signatera's Ability To Risk Stratify And Detect Progression Early
Portfolio Pulse from Benzinga Newsdesk
Natera, Inc. (NASDAQ:NTRA) has announced a new study published in Frontiers in Oncology demonstrating the ability of its molecular residual disease (MRD) test, Signatera, to detect early progression and risk stratify patients with unresectable stage I-III non-small cell lung cancer (NSCLC) treated with definitive radiotherapy. The study showed 82% pre-treatment detection, with 100% longitudinal sensitivity and specificity to disease progression. The study builds on previous data supporting the use of Signatera to detect progression early in resected, early-stage NSCLC patients.
October 04, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Natera's Signatera test has demonstrated high sensitivity and specificity in detecting early progression of NSCLC. This could potentially increase the demand for the test, positively impacting Natera's revenues.
The successful results of the study could increase the demand for Natera's Signatera test among healthcare providers and patients, leading to potential revenue growth for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100